YAFI Online Programming // Disease State Management and Drug Therapy
SARS-CoV-2 and COVID-19
A Primer for Pharmacists and Technicians
After participating in this activity, pharmacists will be able to:
- Describe the difference between SARS-CoV-2 (the virus) and COVID-19 (the viral infection).
- Describe the pandemic’s origins of the current pandemic.
- List signs, symptoms, and concerns related to infection.
- Describe various approaches to help patients and customers implement protective measures.ns
Release Date: March 14, 2020
Expiration Date: December 31, 2021
Pharmacy Tech: $4
20YC36-JXB34 Pharmacy Technician
2.0 hours of CE
UConn faculty assembled this homestudy in response for a high demand to reliable education on coronavirus. It answers questions proposed by our learners.
|The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Pharmacists and pharmacy technicians are eligible to participate in this application-based activity and will receive up to 0.2 CEU (2 contact hours) for completing the activity, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor on- line system and your participation will be recorded with CPE Monitor within 72 hours of submission
Grant funding: None
Cost: $7 for pharmacists, $4 for technicians
Initial Release Date: : March 14, 2020
Expiration Date: December 31,2021
To obtain CPE credit, visit the UConn Online CE Center
Use your NABP E-profile ID and the session code 20YC36-TXF88 for pharmacists or 20YC36-JXB34 for pharmacy technicians to access the online quiz and evaluation.
First- time users must pre-register in the Online CE Center. Test results will be displayed immediately and your participation will be recorded with CPE Mon- itor within 72 hours of completing the requirements.
For questions concerning the online CPE activities, email firstname.lastname@example.org
Jeannette Y. Wick, R.Ph. MDA, FASCP, is the Assistant Director of the Office of Pharmacy Professional Development University of Connecticut (Uconn) School of Pharmacy
C. Michael White, Pharm.D., FCP, FCCP; Professor and Chair, Pharmacy Practice, Uconn School of Pharmacy, Storrs, CT and Director, HOPES Collaborative Group, University of Connecticut and Hartford Hospital, Hartford, CT
Jeffrey R. Aeschlimann, Pharm.D. Is an Associate Professor, UConn School of Pharmacy, Adjunct Associate Professor, UConn School of Medicine, UConn Health, Division of Infectious Diseases
All faculty have no actual or potential conflicts of interest associated with this article.
Disclosure of Discussions of Off-label and Investigational Drug Use
This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
On March 10, 2020, we (the UConn School of Pharmacy) asked our listserv members if they thought a continuing education (CE) activity on the novel coronavirus would be helpful. Within seconds of sending the message, the first answer arrived. Within hours, more than 600 people responded, with 96% of respondents indicating they would like to see a CE. In 24 hours, we exceeded 800 respondents. Almost 60% asked for a written homestudy, so here it is. We’ve used your questions and comments to fashion what we think you need. We thank you for helping us understand what you face in your workplaces, and allowing us to commiserate. We also hope you’ll appreciate some levity, as we will share some amusing anecdotes. Please note that completing this homestudy requires neither facemasks nor hand sanitizer!
The best predictor of a future event is a past event. This is true for many situations and illnesses, and it is true for viral infections that cause serious illnesses. This outbreak is unique in many ways, but it is also similar to several other coronavirus outbreaks and viral epidemics. We can take comfort that we understand viruses better than ever before, and we have seen outbreaks similar to this in various parts of the world. At the same time, we need to respect the fact that this virus is different and we are still learning about its peculiarities.
Full List of References
1. World Health Organization, Coronavirus disease 2019 (COVID-19_Situation Report – 50. Available at https://www.who.int/docs/defaultsource/coronaviruse/situation-reports/20200310-sitrep-50-covid19.pdf?sfvrsn=55e904fb_2. Accessed March 12, 2020.
2. Sun Z, Thilakavathy K, Kumar SS, He G, Liu SV. Potential factors influencing repeated SARS outbreaks in China. Int J Environ Res Public Health. 2020;3;17(5). pii: E1633.
3. Kudo E, Song E,Yockey LJ, et al. Low ambient humidity impairs barrier function and innate resistance against influenza infection. Proc. Natl. Acad. Sci. USA 2019;116:10905–10910.
4. Jackwood MW, Hall D, Handel A. Molecular evolution and emergence of avian gammacoronaviruses. Infect Genet Evol. 2012;12(6):1305-1311.
5. Geller C, Varbanov M, Duval RE. "Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies". Viruses. 2012;4(11):3044–3068.
6. : Depoux A, Martin S, Karafillakis E, Bsd RP, Wilder-Smith A, Larson H. The pandemic of social media panic travels faster than the COVID-19 outbreak. J Travel Med. 2020 Mar 3. pii: taaa031. doi: 10.1093/jtm/taaa031. [Epub ahead of print]
7. Song P, Karako T. COVID-19: Real-time dissemination of scientific information to fight a public health emergency of international concern. Biosci Trends. 2020 Febb 25. doi: 10.5582/bst.2020.01056. [Epub ahead of print]
8. The Lancet. COVID-19: fighting panic with information. Lancet. 2020;395(10224):537. doi: 10.1016/S0140-6736(20)30379-2. PubMed PMID: 32087777.
9. Johns Hopkins University. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available at https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. Accessed March 12, 2020.
10. Centers for Disease Control and Prevention. About Coronavirus Disease 2019 (COVID-19). Available at https://www.cdc.gov/coronavirus/2019-ncov/about/index.html. Accessed March 12, 2020.
11. World Health Organization. Coronavirus. Available at https://www.who.int/health-topics/coronavirus. Accessed March 12, 2020.
12. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). 2020 Mar 8. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-.
Available from http://www.ncbi.nlm.nih.gov/books/NBK554776/. Accessed March 12, 2020.
13. Lauer SA, Grantz KH, Bi Q, et al. The incubation period of Coronavirus Disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020 Mar 10. doi: 10.7326/M20-0504. [Epub ahead of print]
14.v an Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. N Engl J Med. In press. Available at https://www.medrxiv.org/content/10.1101/2020.03.09.20033217v1.full.pdf. Accessed March 12, 2020.
15. Sanche S. Lin YT, ChonggangX, et al. The Novel Coronavirus, 2019-nCoV, is highly contagious and more infectious than initially estimated. Available at https://arxiv.org/abs/2002.03268. Accessed March 12, 2020.
16. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travelers from Wuhan, China, 20–28 January 2020. Euro Surveill. 2020;25.
17. Linton NM, Kobayashi T, Yang Y, et al. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data. J Clin Med. 2020;9(2):pii: E528.
18. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020. [PMID: 31995857] doi:10.1056/NEJMoa2001316 [Epub ahead of print].
19. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. [PMID: 31986264] doi:10.1016/S0140-6736(20)30183-5
20. World Health Organization. Basic protective measures against the new coronavirus. Available at
https://www.who.int/emergencies/diseases/novel-coronavirus2019/advice-for-public. Accessed March 12, 2020.
210. Centers for Disease Control and Prevention. Environmental cleaning and disinfection recommendations. Interim recommendations for US households with suspected/confirmed Coronavirus Disease 2019. Available at https://www.cdc.gov/coronavirus/2019-ncov/community/home/cleaning-disinfection.html. Accessed March 12, 2020.
22. U.S. Environmental Protection Agency. EPA’s registered antimicrobial products for use against novel coronavirus SARS-CoV-2, the cause of COVID-19. Available at https://www.epa.gov/sites/production/files/2020-03/documents/sarscov-2-list_03-03-2020.pdf. Accessed March 12, 2020.
23. Johns Hopkins University. Coronavirus symptoms start about five days after exposure, Johns Hopkins study finds. Available at https://hub.jhu.edu/2020/03/09/coronavirus-incubation-period/. Accessed March 12, 2020.
24. Jernigan DB; CDC COVID-19 Response Team. Update: Public health response to the Coronavirus Disease 2019 outbreak - United States, February 24, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(8):216-219.
25. Liu W, Morse JS, Lalonde T, Xu S. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV Chembiochem (2020 Feb 5), 10.1002/cbic.202000047 [Epub ahead of print]
26. Li G, ED. Cleraq Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Nat Rev Drug Dis (2020), 10.1038/d41573-020-00016-0 [Epub ahead of print]
27. Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PI, Hsueh PR. Arguments in favor of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents. 2020 Mar 5:105933. doi: 10.1016/j.ijantimicag.2020.105933. [Epub ahead of print]
28. Young BE, Ong SWX, Kalimuddin S, et al; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020
Mar 3. doi: 10.1001/jama.2020.3204. [Epub ahead of print]
29. AbbVie partnering with global authorities to determine efficacy of HIV drug in treating COVID-19. March 9, 2020. Available at https://news.abbvie.com/news/press-releases/abbvie-partnering-withglobal-authorities-to-determine-efficacy-hiv-drug-in-treating-covid19.htm. Accessed March 12, 2020.
30. Glick M. Should I shave my beard, can I get COVID-19 twice, and every other question you might have about the coronavirus Available at https://www.popsci.com/story/health/coronavirus-covid-19-faqtransmission/. Accessed March 12, 2020.
31. Rello J, Tejada S, Userovici C, Arvaniti K, Pugin J, Waterer G. Coronavirus Disease 2019 (COVID-19): A critical care perspective beyond China. Anaesth Crit Care Pain Med. 2020 Mar 3. pii: S2352-5568(20)30033-3. doi: 10.1016/j.accpm.2020.03.001. [Epub ahead of print]
32. World Health Organization. Coronavirus disease (COVID-19) advice for the public: When and how to use masks. Available at https://www.who.int/emergencies/diseases/novel-coronavirus2019/advice-for-public/when-and-how-to-use-masks. Accessed March
12. 2020. UCONN You Asked for It Continuing Education March 2020 Page 12
33. Wang L, Yang R, Yuan B, Liu Y, Liu C. The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb. Acta Pharm Sin B. 2015;5(4):310-305.
34. Li SY, Chen C, Zhang HQ, et al. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res. 2005;67(1):18-23.
35. White CM. Dietary supplements pose real dangers to patients. Ann Pharmacother. 2020 Jan 24:1060028019900504. doi: 10.1177/1060028019900504. [Epub ahead of print]
36. Qui J. How China’s “Bat Woman” hunted down viruses from SARS to the new coronavirus. March 11, 2020. Available at https://www.scientificamerican.com/article/how-chinas-bat-womanhunted-down-viruses-from-sars-to-the-new-coronavirus1/. Accessed March 12, 2020.
54. Gottleib S. Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s new efforts to strengthen regulation of dietary supplements by modernizing and reforming FDA’s oversight. February 11,
2019. Retrieved from: https://www.fda.gov/news-events/press-announcements/statementfda-commissioner-scott-gottlieb-md-agencys-new-efforts-strengthenregulation-dietary. Accessed March 1, 2020.
55. U.S. Food and Drug Administration. FDA takes action against 17 companies for illegally selling products claiming to treat Alzheimer’s disease. February 11, 2019. Retrieved from: https://www.fda.gov/news-events/press-announcements/fda-takesaction-against-17-companies-illegally-selling-products-claiming-treatalzheimers-disease. Accessed March 1, 2020.
56. U.S. Federal Trade Commission. FTC and fda send warning letters to companies selling dietary supplements claiming to treat Alzheimer’s disease and remediate or cure other serious illnesses such as Parkinson’s, heart disease, and cancer. Retrieved from: https://www.ftc.gov/news-events/press-releases/2019/02/ftc-fda-sendwarning-letters-companies-selling-dietary. Accessed March 1, 2020.
57. Small B. Aloe, goodbye: company’s claims lacked proof. October 16, 2019. Retrieved from: https://www.consumer.ftc.gov/blog/2019/10/aloegoodbye-companys-claims-lacked-proof?utm_source=govdelivery. Accessed March 1, 2020.
58. Tressler C. FTC reaches settlement with anti-aging pill seller. February 5, 2020. Retrieved from:
https://www.consumer.ftc.gov/blog/2020/02/ftc-reaches-settlementanti-aging-pill-seller?utm_source=govdelivery. Accessed March 1, 2020.